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ABSTRACT 
 
Non-small cell lung cancer (NSCLC) is the most frequent cause of death from cancer worldwide. 
Despite the availability of active chemotherapy regimens and epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors, all advanced patients develop recurrent disease after first-line 
therapy. While heat shock protein 27 (Hsp27) is a stress-induced chaperone that promotes 
acquired resistance in several cancers, its relationship to treatment resistance in NSCLC has not 
been defined. Understanding adaptive responses of acquired resistance will help guide new 
strategies to control NSCLC.  
Hsp27 levels were evaluated in an HCC827 erlotinib-resistant derived cell line (HCC-827Resistant), 
and sensitivity to erlotinib was examined in Hsp27 over-expressing A549 cells.  The role of 
Hsp27 in both erlotinib and cytotoxic treatment resistance was evaluated in HCC827 and A549 
NSCLC cells using the Hsp27 antisense drug OGX-427 and VPC-27, a new functional small 
molecule inhibitor of Hsp27.  The effect of Hsp27 inhibitors in combination with erlotinib was 
also assessed in mice bearing A549 or HCC827 xenografts. 
Hsp27 is induced by erlotinib and protects NSCLC cells from treatment-induced apoptosis, while 
Hsp27 inhibition sensitizes NSCLC cells to erlotinib. Interestingly, increased resistance to 
erlotinib was observed when Hsp27 was increased either in HCC827 ER or over-expressing 
A549 cells. Combining OGX-427 or VPC-27 with erlotinib significantly enhanced antitumor 
effects in vitro and delayed NSCLC cells growth in vivo.  
These data indicate that treatment-induced Hsp27 (by inhibition of EGFR) contributes to the 
development of resistance, and provides pre-clinical proof-of-principle that inhibition of stress 
adaptive pathways mediated by Hsp27 enhances the activity of erlotinib in NSCLC. 
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INTRODUCTION 
 
1. Non-Small Cell Lung Cancer 
Lung cancer is the most prevalent cancer and the leading cause of cancer related death 
worldwide [1]. In North America and Europe it is the third most common cause of mortality for 
men and women and is increasingly observed in non-smokers. Non-small cell lung cancer 
(NSCLC), with a five-year rate survival of only 15%, accounts for approximately 80% of all 
lung cancers. NSCLC is classified histologically in: adenocarcinoma, squamous cell carcinoma 
and large cell carcinoma. The majority of patients present with either locally advanced disease 
(stage III) or metastatic disease (stage IV). Importantly, patients who undergo curative surgical 
resection for apparent localized disease have 50-80% survival rates implying the need for better 
systemic treatment to cure micro-metastatic disease [2]. Therefore, the majority of patients 
require systemic therapy. Several new drugs have been approved for the treatment of metastatic 
adenocarcinoma of the lung: bevacizumab, a monoclonal antibody against VEGF, is approved in 
combination with platinum and paclitaxel [3], nivolumab and pembrolizumab are anti-PD-1 
agents, recently approved in second line in advanced non-squamous lung cancer [4-5]. 
Ramucimurab is a VEGFR-2 monoclonal antibody approved as second line therapy in 
combination with docetaxel after chemotherapy failure [6]. For patients with adenocarcinoma 
harboring ALK mutations, crizotinib represents the drug of choice [7]. Unfortunately, platinum-
based doublet with gemcitabine remains the mainstay of front-line therapy for advanced 
squamous cell carcinoma with modest improvement in survival and quality of life [8].  
 
2. Epidermal Growth Factor Receptor 
Epidermal Growth Factor Receptor (EGFR) is a 170 KDa transmembrane tyrosine kinase 
receptor constitutively activated, either by over-expression or by mutation, in many solid tumors 
[9]. Its overexpression correlates with poor prognosis and resistance to conventional antitumor 
therapies [10]. The EGF receptor structure includes a N-terminal extracellular (EC) domain that 
recognizes and dimerizes with itself and with other receptors like HER-2, HER-3 and HER-4. 
EGF, Amphiregulin, Epiregulin, β-cellulin and TGF-α bind and activate the EC domain of EGFR 
[11].  In normal physiology both homodimerization and heterodimerization of EGFR are 
observed but heterodimerization with other activated receptors is more potent for the activation 
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of downstream signals [12]. The N-terminus is followed by a transmembrane portion and the C-
terminal intracytoplasmic region that contains an ATP-dependent tyrosine kinase (TK) domain. 
This TK domain is able to autophosphorylate at tyrosine residues Y992, Y1045, Y1068, Y1086, 
S1142, Y1148, and Y1173 [13]. EGFR phosphoactivation regulates cell proliferation, survival, 
angiogenesis and metastasis via activation of several down-stream pathways, including mitogen-
activated protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K)/AKT pathway [14]. 
EGFR activation is triggered by hetero-dimerization with other transmembrane receptors, most 
notably HER-3 and HER-2 [15]. However, in NSCLC mutations in the TK domain represent the 
main mechanism of activation of EGFR. These mutations create a conformational change in the 
intracytoplasmic region that leads to a constitutively phosphorylation of EGFR, completely 
independent from the ligands-mediated activation of the receptor [16]. Since it represents one of 
the most important drivers of NSCLC growth and survival, several drugs have been developed 
targeting EGFR. Cetuximab and panitumumab are recombinant monoclonal antibodies that 
recognize the EC portion of EGFR [17]. Erlotinib and gefitinib are small molecule EGFR 
inhibitors that binds the ATP-binding site of the intracellular TK domain of EGFR [18]. Afatinib 
is a new generation irreversible EGFR-TKI that affects both EGFR and HER-2 [19]. Afatinib, 
erlotinib and gefitinib significantly improve survival in patients with metastatic NSCLC and are 
approved for the first line therapy of patients with metastatic adenocarcinoma of the lung 
harboring EGFR activating mutations [20-23]. Although the development of EGFR targeting 
drugs have modified the clinical landscape for patients with metastatic NSCLC, unfortunately 
therapeutic resistance and death from disease remains very common. Resistance is often 
associated with the development of second EGFR mutations (i.e. T790M,) that interfere with 
binding to the inhibitors to maintain EGFR activity [24], which can be partially overcome by 
increasing TKI potency [25] or by co-targeting other pathways up-regulated during treatment. 
For example, there is evidence that co-targeting Heat shock protein 90 (Hsp90), a molecular 
chaperone known to interact with EGFR, can increase EGFR molecular degradation even in the 
presence of mutations [26]. Other heat shock chaperones, like Hsp27 (HspB1), play a pivotal 
role in stress responses to treatment, but their role has not been investigated in the resistance to 
EGFR inhibitors in NSCLC. Better understanding the mechanisms of resistance to anti EGFR 
drugs is necessary to re-sensitize cancer cells and continue to improve outcomes, and to better 
stratify and predict treatment response to control resistance.  
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3. Heat Shock Protein 27 (Hsp27) 
Hsp27 is a stress-induced ATP-independent molecular chaperone that is transcriptionally 
regulated by HSF-1, HIF-1, and other factors influenced by cell type and cell context [27-28].  
It is involved in the regulation of protein homeostasis, in stabilizing unfolding proteins, as well 
as the actin-cytoskeleton [29-31]. Hsp27 promotes survival by binding to both cytochrome c and 
caspase 3 to inhibit intrinsic apoptotic pathway activation, and facilitates epithelial-mesenchymal 
transition and expression of metastatic genes [32-33]. Its activity is regulated by phosphorylation 
that controls Hsp27 oligomerization  and self-association [34]. In prostate cancer (Pca), Hsp27 
controls treatment resistance facilitating cell survival, invasion and migration [33, 35-36]. Hsp27 
expression increases after androgen deprivation therapy (ADT) and it is highly expressed in 
castration resistant prostate cancer, activating alternative molecular pathways (AR, IGF-1, and 
IL-6) that support cell proliferation and survival independently from castration [37-39]. 
Moreover, Hsp27 is also involved in the control of endoplasmic reticular (ER) stress [40]. These 
data support Hsp27 as a therapeutic “hyper-node”, a target situated as a ‘Hub” at the center of 
many pathways, regulating response of cells to therapeutic stress and contributing to the 
development of therapy resistance.  
 
4. Targeting Hsp27 
Hsp27 is a difficult protein to target because, unlike Hsp90, it lacks an active site or ATP-
binding pocket. The Anti Sense Oligonucleotide (ASO) OGX-427 is the only Hsp27 inhibitor 
that showed to efficiently block Hsp27 functions in preclinical models of prostate cancer [41]. It 
was developed by Dr. Gleave’s group at the Vancouver Prostate Centre and demonstrated high 
anti-cancer activity in vitro and in vivo prostate cancer models [33, 42]. The stability of the drug 
was significantly improved by the presence of a 2′-methoxyethyl phosphorothioate group that 
reduce the nucleases degradation improving the in vivo tissue half-life of the drug (almost 7 
day). Hsp27 ASO enhances apoptosis and delays prostate tumor progression and chemo-
sensitizes bladder, prostate, ovarian and uterine cancer to paclitaxel [43-44], and colorectal 
cancer to irinotecan [45].  Considering the promising activity of the drug, a phase I clinical trials 
with OGX-427, alone or in combination with docetaxel, was conducted in patients affected by 
prostate, bladder, breast and lung cancer. The study demonstrated that OGX-427 was well 
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tolerated at high doses (800 and 1000 mg) also in combination with docetaxel [46]. A recent 
phase II trial investigating OGX-427 with or without prednisone (P) on progression in chemo-
naive metastatic CRPC enrolled 72 patients. At 12 weeks, the proportion of patients that were 
progression free was 71% in OGX-427+P arm and 40% in P only arm. A ≥50% PSA decline 
occurred in 50% of patients on OGX-427+P compared to 20% on P. Measurable disease 
response occurred in 44% on OGX-427+P and 0 patients on P. Circulating Tumor Cells 
conversion from ≥5 to <5/7.5 ml blood occurred in 55% evaluable patients on OGX-427+P and 
41% treated with P. These results confirm, for the first time, single agent activity for an Hsp27 
inhibitor in cancer, supporting the central role of Hsp27 in the development of prostate cancer 
[47]. OGX-427 also showed activity in a phase I trial in superficial bladder cancer, inducing 38% 
of complete pathologic response. These results confirm, for the first time, single agent activity 
for an Hsp27 inhibitor [48]. However, while the clinical results of OGX-427 are promising, a 
more potent and orally active inhibitor, with higher stability, may improve cancer outcome.   
So far, no small molecules have showed to efficiently inhibit Hsp-27. Because of the lack of an 
ATP binding domain and its extremely dynamic structure [49], targeting Hsp27 is challenging. 
Most sHsps assemble into large oligomers which stably interact with misfolded or other specific 
client proteins, facilitating proteostasis along with signaling and transcriptional pathways 
activation. Depending on the number of subunits, these Hsp27 oligomers have diverse 
architectures and symmetries that determine the spectrum of their highly context-dependent 
protein interactome.  Assembly and depolymerisation of Hsp27 subunits into large to small 
complexes is dynamic and context dependent, mediated by the phosphorylation status of 3 serine 
residues (Ser15, Ser78, Ser82) in the N-terminal region of Hsp27 [50-51]. Thus, the N-terminal 
domain modulates dynamics of Hsp27 oligomer assembly and is critical for the affinity of Hsp27 
with client proteins. 
In this study we show that Hsp27 is expressed in nearly 70-80% of NSCLC patients and that 
erlotinib increases levels of both total and phosphorylated Hsp27 via activation of HSF-1. Using 
Hsp27 functional biochemical screening assays, we identified a new small molecule drug, VPC-
27, that inhibits Hsp27 phosphor-activation after treatment stress in several cancer cells with a 
good tolerability profile in mice studies.  
Hsp27 inhibition with OGX-427 or the new small molecule Hsp27 inhibitor VPC-27 
synergistically increased erlotinib-induced apoptosis and inhibition of A549 and HCC827 lung 
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cancer cell growth in vitro and in vivo. These results illustrate that co-targeting treatment-
induced adaptive responses mediated by Hsp27 can sensitize lung cancer cells to EGFR TKIs 
and cytotoxic therapies.  
 
MATERIALS AND METHODS 
 
FRET  
Fluorescence Resonance Electricity Transmission (FRET) assay was performed in Corning 384 
wells, black flat bottom plates. 20µL of Buffer (10mM Tris pH 8.4), 5µL Inhibitor (200µM), 
10µL Rodamine Red:Hsp27 (45nM),  10µL QSY21:Hsp27 (0.675µL) was successively added to 
sample wells. Samples were incubated for 20minutes at 37°C prior to fluorescence 
measurements using TECAN INFINITE M200PRO, excitation wavelength of 515nm and 
emission wavelength of 590nm. 
 
FP 
After FRET measurements, 10µL of wt-Hsp27 (2.475µM), 10µL of Insulin-FITC (1.56µM) and 
10µM TCEP (75mM) was added to appropriate wells with 2 minute equilibration period in 
between each addition. The plate was then incubated at 42°C for 20 minutes and Fluorescence 
Polarization (FP) measurements were taken (TECAN INFINITE F500 excitation wavelength 
485nM and emission wavelength at 535nM). 
 
Aggregation 
HSF1 -/- MEF cells were lysed using 25mM Tris pH7.4, 150mM NaCl, 1mM EDTA, 1% NP40 
lysis buffer. BSA 100g/L and 1M DTT was prepared in advance and was thawed at room 
temperature. Using Corning 96well plate, in each sample wells, 20µL of BSA, 100µL of cell 
lysates at 1mg/mL, 1µL of DMSO/test inhibitor, and ±1µL of 1mg/mL wt-Hsp27 successively 
added, PBS was used to complete to total volume of 320µL. After 5 minutes incubation at room 
temperature, the plate was subjected to 3-hour kinetic cycle with reading at 340nM at 42°C, 
shaken for 10 seconds prior to read, and was read every 5 minutes. 
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Oligomerization  
A 12 steps glycerol gradient ranging from 3.33% to 40% was constructed with 3.33% stepwise 
increments with total volume of 9mL. Cell lysates were prepared in 25mM HEPES pH 7.4, 1mM 
EDTA, 3.33% Glycerol, 0.1mM PMSF, 1mM DTT and sonicated for 10 seconds. Equal amount 
of proteins, measured by BCA analysis, were loaded onto the glycerol gradient and subjected to 
ultracentrifugation for 18hours at 36 000RPM (160 000 x G) using SW41Ti swing bucket rotor. 
Three-hundred µL fractions were collected into corning 96well plates using a mini pump and 
stored at -30°C for WB analysis. Glycerol gradient assay buffer (25mM HEPES pH 7.4, 1mM 
EDTA, 1mM DTT) was used to make the glycerol gradients. 
 
Tumor Tissue Arrays 
Six hundred nine cases of primary NSCLCs with follow-up data diagnosed between 1978 and 
2002 were identified from the archives of St Paul’s Hospital, Vancouver, British Columbia. The 
paraffin-embedded tissue blocks were used to construct a duplicate core Tissue microarray 
(TMA). After review of the tissue cores, 588 cases, consisting of NSCLC met the criteria for 
inclusion in this study. Carcinoids, atypical carcinoids, large cell neuroendocrine carcinoma and 
metastatic tumors were all excluded. H&E-stained sections were reviewed and sub-classified as 
follows: 243 adenocarcinoma (AD), 272 squamous cell carcinoma (SCC), 35 large cell 
carcinoma (LCC), 32 non-small cell carcinoma, and 6 other (carcinoma, giant cell carcinoma). 
 
Immunohistochemistry 
Immunohistochemical staining was conducted by Ventana autostainer model Discover XT  
(Ventana Medical System, Tuscan, Arizona) with enzyme labeled biotin streptavidin system and 
solvent resistant DAB Map kit by using mouse monoclonal Hsp27 antibody from Novocastra™ 
now Leica Biosystems Newcastle Ltd, Newcastle, UK and polyclonal phosphor-Hsp27 (Ser82) 
antibody from Cell Signaling Technology, Danvers, MA. To ensure specificity of Hsp27 and p-
Hsp27 antibodies, small cell lung carcinoma and benign prostate gland basal cells tissues were 
used as internal negative and positive controls. 
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Lung Cancer Cell Lines and Reagents 
A549 (EGFR wild-type and KRAS mutated: G12S) and HCC827 (EGFR mutated: delE746-
A750) cells were purchased from the American Type Culture Collection and authenticated with 
short tandem repeat (STR) profile analysis in Jan 2013 by Genetic Resources Core Facility at 
John Hopkins. Cells were maintained in RPMI-1640 media (Invitrogen Life Technologies) 
containing 5% fetal bovine serum (FBS; Invitrogen Life Technologies). Erlotinib was purchased 
from LC Laboratories. A549 cell lines overexpressing Hsp27 (A549Hsp27) were developed by 
stably transfecting cells with an Hsp27 vector by lentivirus transfection, as previously described 
52. HCC827Resistant cell lines were developed by maintaining HCC827Parental in 500nM erlotinib 
for 3 months. Genomic sequencing was done to confirm cell line identity. Antibodies: anti-HSF-
1 from Santa Cruz Biotechnology; anti-Hsp27 from StressGen; anti- phospho-EGFR (Tyr1068), 
anti-EGFR, anti-cleaved PARP, anti-phospho-Hsp27 (Ser82), anti-cleaved caspase3, anti-
caspase3, anti-phospho-ERK and anti-phospho-Akt (Ser423) were purchased from Cell 
Signaling Technology; and anti-β-Actin from Sigma-Aldrich.  
 
ASO Transfection 
Cells were transfected with antisense as described previously [53]. Hsp27 ASO and scrambled 
(ScrB) control oligonucleotide sequences were manufactured by ISIS Pharmaceuticals (Carlsbad, 
CA, USA) and supplied by OncoGenex Technologies (Vancouver, British Columbia, Canada). 
The sequence of OGX-427 corresponds to the human Hsp27 translation initiation site (5′-
GGGACGCGGCGCTCGGTCAT-3′). The sequence of heat shock factor 1 (HSF-1) siRNA 
corresponds to the human HSF-1 site (sc-35611; Santa Cruz Biotechnology). A scrambled 
siRNA (5‘-CAGCGCUGACAACAGUUUCAU-3‘; Dharmacon) was used as a control for RNA 
interference experiments. Transfections were performed by using Oligofectamine (Invitrogen), 
as previously described [54]. 
 
Western Blot Analysis 
Total proteins were extracted using RIPA buffer (50mM Tris, pH 7.2, 1% NP-40, 0.1% 
deoxycholate, 0.1% SDS, 100mM NaCl, Roche complete protease inhibitor cocktail) and 
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centrifuged to remove the insoluble material. Western Blots analysis was performed as described 
previously [53].  
 
Quantitative reverse transcriptase PCR 
RNA extraction and reverse transcriptase PCR (RT-PCR) were carried out as described 
previously [42]. Real-time monitoring of PCR amplification of cDNA was carried out using the 
following primer pairs and probes: Hsp27 (Hs03044127_g1), HSF1 (Hs00232134_m1), and 
GAPDH (Hs03929097_g1; Applied Biosystems) on the ABI PRISM 7900 HT Sequence 
Detection System (Applied Biosystems) with a TaqMan Gene Expression Master Mix (Applied 
Biosystems). Target gene expression was normalized to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) levels in the respective samples as an internal control. The results are 
representative of at least 3 independent experiments.  
 
In Vitro Cell Growth Assay 
Cells were plated in 12-well plates, and transfected with siRNA for 1 day or ASO for 2 days as 
indicated followed by erlotinib treatment at various concentrations for 48 hours. For VPC-27 
experiments, cells were plated in 96-well plates and treated with VPC-27, erlotinib or the 
combination of the two drugs. Cell viability was then assessed using crystal violet assay as 
described previously [55]. Absorbance was determined with a micro-culture plate reader (Becton 
Dickinson Labware) at 560 nm. Changes in cell viability were calculated as percentage relative 
to the vehicle-treated cells. Each assay was performed in triplicate. The combination index (CI) 
was evaluated using CalcuSyn dose–effect analysis software (Biosoft) as described previously 
[55]. CI was calculated at ED50, ED75 and ED90. 
 
Cell Cycle Analysis 
Cell cycle populations were analyzed by propidium iodide–staining using flow cytometry as 
previously described [53].  
 
Animal manipulation and Assessment of In Vivo Tumor Growth 
For in vivo xenograft studies, 6x 106 A549 cells were inoculated s.c. in the flank of 6- to 8-week-
old male athymic nude mice (Harlan Sprague Dawley, Inc.) via a 27-gauge needle under 
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isoflurane anesthesia. When tumors reached 100mm3, mice were randomly selected for treatment 
with 50 mg/kg erlotinib (formulated in 0.5% methylcellulose + 0.1% Tween-80) orally 
administered once daily for 5 days per week and 15 mg/kg OGX-427 or ScrB injected i.p. once 
daily for 7 days and three times per week thereafter. Each experimental group consisted of 8 
mice. For VPC-27 in vivo experiment, HCC827 cells were inoculated s.c. in the flank of 6-8 
weeks old female athymic mice, as described above. When tumors reached 150-200 mm3, mice 
were randomized to receive erlotinib 15 mg/Kg,  VPC-27 10 mg/kg or the combination of the 
drugs (formulated in 0.5% methylcellulose + 0.1% Tween-80) orally administered, 3 days a 
week. Each experimental group consisted of 8 mice. Tumor volume measurements were 
performed once weekly for A549 and twice weekly for HCC827 and calculated by the formula 
length x width x depth x 0.5236. Data points were expressed as average tumor volume ± SEM. 
All animal procedures were performed according to the guidelines of the Canadian Council on 
Animal Care and with appropriate institutional certification. 
 
Luciferase assay 
HCC827 and A549 cells were transfected with HSE luciferase plasmid and pRL-TK as internal 
control using lipofectin reagent (Invitrogen) followed by erlotinib treatment for 24 hrs at the 
indicated concentrations.  The luciferase activity was measured using a dual-luciferase reporter 
assay system (Promega) and a microplate luminometer (Tecan). The results are representative of 
3 independent experiments. 
 
Statistical Analysis      
Differences between the two groups were compared using Student’s t-test and Mann-Whitney U 
test. For the in vivo analysis ANOVA test was used. All statistical calculations were performed 
using Statview 5.0 software (Abacus Concepts, Inc.), and P values < 0.05 were considered 
significant. 
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RESULTS 
 
Identification of new small molecule inhibitors of Hsp27 
In order to identify functional Hsp27 inhibitors, focused small molecule libraries were first 
screened using a combined Fluorescence Resonance Electricity Transmission (FRET) and 
Fluorescence Polarization (FP) based assays. The compounds that passed the combined 
screening were further analyzed using protein aggregation and Hsp27 trypsin digestion. Only one 
of 1,280 small molecules tested, VPC-27, passed all the phases of the screening. FRET assay 
relies on the distance-dependent transfer of energy from a donor to an acceptor molecule (in our 
experiment Rhodamine Red and QSY21, respectively). Due to its sensitivity to distance, FRET 
has been used to investigate molecular interactions 56. Two pools of purified Hsp27 were 
labelled with QSY21 (Hsp27-QSY21) and Rhodamine Red (Hsp27-RR). FRET assay results for 
VPC-27 showed that this molecule affects Hsp27 fluorescence quenching of Rhodamine Red by 
QSY-21 when the two protein pools are mixed. This confirms that VPC-27 is able to interact to 
Hsp27 (Fig. 1). 
 
Figure 1. VPC-27 interacts with Hsp27. A mixture of Hsp27-RR and Hsp27-QSY21 were used as negative control 
(gray squares), Hsp27-RR alone (grey diamonds) or combined with VPC-27 (black triangles) as positive control. 
When a drug interferes with Hsp27 ability to exchange subunit, we observed a reduced quenching of the Rhodamine 
Red signal with increased VPC-27 concentrations (red squares). 
 
Hsp27 binds to unfolded proteins, inhibiting proteins aggregation, precipitations and degradation 
29. Using FP assay we evaluated the ability of VPC-27 to inhibit the interaction of Hsp27 with 
unfolded insulin. As showed in figure 2A, the addiction of VPC-27 to wt-Hsp27 and insulin-
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FITC, significantly decreased the formation of the Hsp27-insulin complex, as revealed by 
reduction of polarization. Moreover, to confirm the same effect on other proteins, we used MEF 
HSF1-/- cells. These cells do not express HSF-1, the main transcription factor for Hsp27, and 
were used as source of cellular proteins. As showed in figure 2B, after the addition of Hsp27 to 
the protein lysate, aggregation was significantly inhibited. Interestingly, VPC-27 treatment 
reverted Hsp27 effects, increasing the protein aggregation. These data demonstrated that VPC-27 
affects Hsp27 ability to interact to unfolded proteins, one of the most important biological 
functions of Hsp27. 
 
 
 
Figure 2. VPC-27 interferes with Hsp-27 - unfolded proteins binding. (A) wt-Hsp27 was incubated with Insulin-
FITC and 10µM of TCEP to induce Insulin unfolded aggregation. Fluorescence polarization of Insulin was 
evaluated after treatment with increasing concentrations of VPC-27.  (B) Protein lysate enriched with BSA from 
MEF HSF1-/- cells not expressing Hsp27 was used as source of proteins. The assay was conducted adding Hsp27 
and DTT at 10 uM to induce protein aggregation in presence of VPC-27 10 µM or DMSO.  MEF HSF1-/-  cells 
lysate, BSA and DTT without Hsp27 were used as negative control. Results were adjusted by Hsp27 values alone. 
 
VPC-27 interferes with Hsp27 depolymerisation and reduces Hsp27 phosphorylation 
Hsp27 activity is triggered by Hsp27 phosphorylation that is able to shift the equilibrium of the 
large polymers to small oligomers and expose the hydrophobic surface of the protein in order to 
enhance its chaperone activity 31, 34. To test whether VPC-27 affected or not Hsp27 
phosphorylation, HCC827 NSCLC cancer cells were treated with increasing concentration of the 
drug for 24 hours in basal condition (Fig. 3A) and after Hsp27 phosphorylation stimulation using 
TNF-α or Heat shock (Fig. 3 B). VPC-27 was able to reduce Hsp27 phosphorylation in basal 
condition and to prevent it in presence of stress stimuli, confirming its activity on Hsp27 
activation. 
 
A B 
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Figure 3. VPC-27 inhibits Hsp27 phosphorylation. Western Blotting analysis shows the dose-dependent effect of 
VPC-27 on Hsp-27 phosphorylation in NSCLC cell lines HCC827 in basal condition (A) and in A549 after Heat 
Shock (B). Cells were treated in RPMI with 2% of FBS with VPC-27 or DMSO for 24 hours. Proteins were 
extracted using RIPA buffer. Vinculin was used as loading control 
 
Moreover, to confirm the effect of VPC-27 on Hsp27 polymerization, we analyzed the 
distribution of the different oligomers of Hsp27 in a glycerol gradient gel with and without VPC-
27 treatment. Interestingly, we observed a shift of WT Hsp27 from the smaller to the bigger 
oligomers in HCC827 cells after VPC-27 treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. VPC-27 affects Hsp27 de-polymerisation. Whole protein lysate from HCC827 cells treated with DMSO 
or VPC-27 was added to a solution containing increasing glycerol concentrations (from 40 to 3.33 %). The fractions 
were centrifuged for 18hours at 36,000 RPM (160 000 x G) using SW41Ti swing bucket rotor.  The fractions 
collected from the different glycerol gradient were loaded in a polyacrylamide gel for western blotting analysis. The 
graphical representation of the glycerol gradient WB shows VPC-27 treatment inhibits Hsp27 to depolymerisation 
from large to smaller forms. 
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Hsp27 and phospho-Hsp27 are highly expressed in human NSCLC.  
Hsp27 has been reported to be highly and uniformly expressed in several cancers [57-61].  To 
assess the distribution of Hsp27 and phospho-Hsp27 expression in human NSCLC, we 
performed immunostaining of human NSCLC spotted on tissue microarrays (TMA). Positive 
Hsp27 staining was noted in 176 of 214 squamous cell carcinomas (82.2%), 139 of 195 
adenocarcinomas (71.3%) and 21 of 31 large cell carcinomas (67.7%) (Fig. 5A). Positive 
phospho-Hsp27 staining was observed in 184 of 212 squamous cell carcinomas (86.8%), 147 of 
184 adenocarcinomas (79.9%) and 27 of 31 large cell carcinomas (87.1%) (Fig. 5B). These data 
suggest that both Hsp27 and phospho-Hsp27 are frequently expressed in NSCLC.  
 
 
 
Figure 5. Hsp27 and phosphorylated Hsp27 expression in NSCLC. (A) Paraffin-embedded tissue blocks were 
used to construct a duplicate core tissue microarray (TMA). Hsp27 expression was evaluated in 440 NSCLC tissues. 
H&E-stained sections were reviewed and sub-classified as follows: 214 squamous cell carcinoma (SCC), 195 
adenocarcinoma (AD) and 31 large cell carcinoma (LCC). (B) phospho-Hsp27 expression was evaluated in 427 
NSCLC tissues. H&E-stained sections were reviewed and sub-classified as follows: 212 SCC, 184 AD and 31 LCC. 
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Erlotinib induces Hsp27 expression in A549 and HCC827 cells via HSF-1 activation. 
To evaluate the effect of erlotinib on Hsp27 expression and phosphorylation, we used erlotinib-
resistant A549 (IC25 = 4.2µM) and erlotinib-sensitive HCC827 NSCLC cell lines (IC25 = 8nM). 
Erlotinib caused a clear decrease of EGFR phosphorylation associated with a time- and dose- 
dependent increase of total Hsp27 and phospho-Hsp27 with a parallel increase of apoptosis as 
detected by cleaved PARP. (Fig. 6A) 
 
 
 
Figure 6. Erlotinib induces Hsp27/phospho-Hsp27 expression. (A) A549 (left panels) and HCC827  (right 
panels) cells were treated with erlotinib for up to 72h (upper panels) or for 48 H at increasing doses (lower panels), 
and Western Blots were performed with antibodies against p-Hsp27, total Hsp27, P-EGFR, total EGFR, Cleaved 
PARP. β-actin and vinculin were used as loading control.  
 
Because HSF-1 is a key regulator of Hsp27 expression, we evaluated the effect of erlotinib on 
HSF-1 activity. Erlotinib led to increased HSF-1 and Hsp27 both at the protein (Fig. 7A, left 
panel) and mRNA levels in A549 and HCC827 cell lines (Fig. 7A, right panel). Moreover, 
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silencing HSF-1 using siRNA abrogated erlotinib-induced up-regulation of Hsp27 (Fig. 7B). 
Hsp27 can be phosphorylated by p90Rsk downstream of pAkt and pErk [39], two pathways 
downstream of pEGFR, and therefore inhibited by erlotinib. While levels of pAkt and pErk do 
not increase after erlotinib, increase of pHsp27 reflect increased HSF-1 mediated transcription of 
total Hsp27. Collectively these data indicate that stress-induced activation of HSF-1 by erlotinib 
leads to increased total Hsp27 levels and a consequent increase in p-Hsp27. This finding, in 
addition to the positive staining in TMA samples from a variety of NSCLC, implicates Hsp27 in 
erlotinib resistance and highlights it is a therapeutic target in combination therapy with EGFR 
TKI.  
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Figure 7. Erlotinib induces Hsp27 expression via activation of HSF-1. (A) A549 and HCC827 cells were treated 
with erlotinib for 48 hours. (Left panel) Western Blots were performed against p-EGFR, total EGFR, p-Hsp27, total 
Hsp27, HSF-1, and -actin was used as loading control. (Right panel) Hsp27 and HSF-1 mRNA levels were 
measured by real time PCR 48h after treatment. (B) A549 and HCC827 cells were transfected daily with 20nM 
HSF-1 siRNA or Scramble siRNA for 1 day, followed by erlotinib treatment for 48 hours. (Left panel) HSF-1, 
pEGFR, total EGFR, Hsp27 and -actin as loading control were detected by Western Blot analysis. (Right panel) 
mRNA levels were analyzed by real time PCR 48h after treatments. Bars, SD. ** and *, differ from control P < 0.01 
and P < 0.05, respectively. 
 
Hsp27 overexpression reduces erlotinib-induced cell death.  
We previously reported that Hsp27 overexpression promotes cell survival and confers resistance 
to paclitaxel in prostate and bladder cancer cell lines [38, 43]. Here we investigated the effects of 
Hsp27 over-expression on A549 cell growth in the presence of erlotinib by comparing cell 
viability of a stably transfected A549 cell line (A549Hsp27) to A549Empty controls after increasing 
doses of erlotinib. Cell viability curves in figure 8A confirm that A549Hsp27 cells are more 
resistant to erlotinib compared to control A549Empty cells. Moreover, western blot analysis (Fig. 
8B) indicates reduced PARP cleavage at 10 and 20 µM erlotinib in the A549Hsp27 vs. A549Empty 
cell lines confirming that overexpression of Hsp27 protects lung cancer cells from erlotinib-
induced apoptosis.  
To better evaluate the role of Hsp27 in erlotinib resistance we established an HCC827 resistant 
cell line (IC25 = 1µM) by maintaining HCC827 parental cells in 500nM erlotinib for 3 months 
(Fig. 8C).  Fig 8D shows reduced cleaved PARP and increased expression of Hsp27 in 
HCC827resistant cells compared to parental. These findings further implicate Hsp27 in erlotinib 
resistance both when Hsp27 becomes endogenously over-expressed in response to treatment 
(HCC827resistant) and when it is highly expressed via stable transfection (A549Hsp27).  
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Figure 8.  Hsp27 overexpression induces erlotinib resistance. (A) A549 cells were stably transfected either with 
an empty vector (A549Empty) or with a vector containing wild-type Hsp27 (A549Hsp27). Cell viability was determined 
after increasing erlotinib doses 72h after treatment. (B) p-EGFR, total EGFR, Hsp27, cleaved PARP, and -actin as 
loading control were detected by Western Blot in both cell lines after 72h erlotinib treatment. (C) HCC827 erlotinib-
resistant cell lines (HCC827resistant) were established maintaining HCC827parental cells in 500nM erlotinib for 3 
months. Hsp27 levels were measured by Western Blots (insert). Cell viability was determined after increasing 
erlotinib doses 72h after treatment. (D) Cleaved PARP, Hsp27, p-Hsp27, p-EGFR, total EGFR, and vinculin as 
loading control were detected by Western Blot for resistant cells at 500nM erlotinib and parental cells at 0 and 72h 
after 200nM erlotinib. 
 
Hsp27 inhibition, by OGX-427 or VPC-27, sensitizes both HCC827 and A549 to erlotinib. 
Since the preceding results links Hsp27 to erlotinib resistance we hypothesized that co-targeting 
this chaperone in combination with EGFR TKI will increase erlotinib efficacy. Cell viability was 
assessed in A549 and HCC827 cells after erlotinib or OGX-427 mono- and combination-therapy. 
OGX-427 leads to increased cell death compared to single agent therapy when used in 
combination with erlotinib (Fig. 9A). Combination Index, calculated at a ratio OGX-
427:erlotinib 1:200 for A549 and 20:1 for HCC827, confirms a synergistic effect for this drug 
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combination (Fig. 9B). Increased levels of cleaved PARP and caspase 3 assessed by Western 
Blotting (Fig. 9C), together with increased subG0 apoptotic fraction assessed by PI staining–
based FACS analysis (Fig. 9D) confirmed that OGX-427 enhances erlotinib-induced apoptosis.  
 
Figure 9. OGX-427 sensitizes both HCC827 and A549 to erlotinib. (A) A549 and HCC827 cells were transfected 
with 50nM OGX-427 or ScrB for 2 days and treated with the indicated concentration of erlotinib for 48 hours after 
the second transfection. Cell viability was determined by crystal violet assay 48h after erlotinib treatment. (B) 
Combination index analysis for erlotinib and OGX-427 treatment in A549 and HCC827 cell lines was performed 
according to the Chou and Talalay method [49]. (C)  p-EGFR, total EGFR, total Hsp27, cleaved PARP, cleaved 
caspase-3, caspase-3 and β-actin, as loading control, were detected by Western Blot analysis. Inhibition of erlotinib-
induced Hsp27 enhances cell apoptosis in both A549 and HCC827. (D) Cells were transfected with 50nM OGX-427 
or ScrB for 2 days and treated with erlotinib (A549 at 10µM and HCC827 at 2.5nM) for 48 hours after the second 
transfection. Flow cytometry analysis of A549 and HCC827 show an increase in subG0 and decrease in G0/G1. SD. 
** and *, differ from control (P < 0.01 and P < 0.05, respectively). 
 
The same experiments on cell viability was conducted in HCC827 and A549 cells combining 
VPC-27 and erlotinib. As demonstrated in figure 10, VPC-27 treatment had the same effect of 
erlotinib in both cell lines in monotherapy. However, the combination of the two drugs 
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significantly inhibited cell survival in both cell models, confirming that Hsp27 inhibition 
increases NSCLC cancer cell sensitivity to EGFR inhibitor erlotinib. 
 
 
 
 
Figure 10. VPC-27 increases cells sensitivity to erlotinib. Percentage of survival cells after treatment with 
increasing doses of VPC-27, erlotinib or the combination of the two drugs, in HCC827 (A) and A549 (B) NSCLC 
cell lines. The cells were plated in 96 well plate and treated for 4 days. Cells were fixed with glutaraldehyde 1% and 
colored with crystal violet. The number of survived cells was evaluated measuring absorbance of crystal violet at 
520 nm. Error bars: standard deviation. T- test values:  * p<0.05,  ** p<0.001. 
 
Combining OGX-427 or VPC-27 with erlotinib enhances tumor growth inhibition in vivo 
The combination effect of OGX-427 or VPC-27 and erlotinib was next evaluated in an in vivo 
model using A549 and HCC827 xenografts, respectively. Tumor-bearing mice were randomly 
assigned to groups treated with ScrB+Diluent, ScrB+Erlotinib, OGX-427+Diluent or OGX-
427+Erlotinib when A549 tumors reached 100 mm3. Mean tumor volume were similar in all 
groups at baseline and all treatments were performed for 7 weeks. Consistent with in vitro 
findings, OGX-427 was able to reduce Hsp27 protein level and the combination therapy of 
OGX-427 plus erlotinib significantly reduced tumor growth rates (Fig. 11A-C) compared with 
all other groups (P=0.0002, 0.03 and 0.01 against ScrB+Diluent, ScrB+Erlotinib and OGX-
427+Diluent, respectively). Moreover, OGX-427 plus erlotinib-treated tumors had higher 
apoptotic rates as shown by increased TUNEL staining compared with the other groups (Fig. 
9D). These studies indicated that this combination treatment significantly delays growth and 
increases apoptotic rates of A549 xenografts. 
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Figure 11. OGX-427 plus erlotinib delays A549 xenograft growth in vivo. (A) A549 cells were inoculated s.c. 
and when tumor volume reached 50-100mm3, mice were treated with scrambled (ScrB) control+diluent, 
ScrB+erlotinib, OGX-427+diluent or OGX-427+erlotinib as described in Materials and Methods. Each data point 
represents the mean tumor volume in each group containing 8 mice ± SEM. *, differ from ScrB+diluent, 
ScrB+erlotinib, OGX-427+diluents or OGX-427+erlotinib treatment group (P<0.05). (B) Tumor volume changes 
were evaluated three weeks after starting the treatment. We set as 0 that at which tumor volume doubled after 
starting the treatment. (C) Hsp27 down regulation after OGX-427 treatment was evaluated by Western Blot. Three 
animals were (D) Tumors were collected after 49 days and TUNEL were evaluated by immunohistochemical 
analysis (original magnification: x200). used as representative samples from each group. 
 
The same effect was observed with VPC-27. HCC827 bearing mice were treated with vehicle 
only, erlotinib, VPC-27 or VPC-27+erlotinib when HCC827 tumors reached 150-200 mm3. As 
expected, erlotinib inhibited tumor growth but interestingly also VPC-27 showed to significantly 
affect tumor growth as single agent. As observed in vitro, the combination of VPC-27 and 
erlotinib was the most active therapeutic strategy compared with all other groups (Fig. 12A). 
Moreover, we were able to confirm the on target effect of VPC-27 on p-Hsp27 also in vivo, as 
demonstrated by the reduction of the levels of p-Hsp27 evaluated by immunohistochemistry 
(Fig. 12B). 
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Figure 12.  VPC-27 inhibits tumor growth and enhances erlotinib activity in HCC827 xenograft mice. (A) 
HCC827 cells were inoculated s.c. in Balbc mice and when tumor volume reached 150 mm3 mice were treated with 
vehicle (ctrl), vehicle+erlotinib, vehicle+VPC-27 or VPC-27+erlotinib as described in Materials and Methods. Each 
data point represents the mean tumor volume in each group containing 8 mice ± SEM. **/***, differ from vehicle, 
erlotinib, VPC-27 or VPC-27+erlotinib treatment group (***P<0.01, P< 0.001). (B) Tumors were collected at the 
endpoint of the mice and p-Hsp27 was evaluated by immunohistochemical analysis. A representative sample from 
each group is represented. 
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DISCUSSION 
 
Anti-cancer treatments induce stress responses that inhibit apoptosis and promote emergence of 
an acquired treatment-resistant phenotype. Molecular chaperones play key roles in these stress 
responses by regulating many pro-survival signaling and transcriptional networks. Two strategies 
have recently emerged that are revolutionizing the treatment landscape in cancer: the use of 
molecular-targeted agents and the selective inhibition of adaptive responses. In this work we 
focus on the role of treatment-induced Hsp27 expression and treatment response in NSCLC, the 
most common type of lung cancer and the largest cause of cancer-related death worldwide, 
where chemotherapy or EGFR-TKIs are first-line treatment. EGFR belongs to a family of 
membrane bound receptors with a tyrosine kinase domain that, when phosphorylated, activates a 
number of downstream pro-survival pathways including the PI3K/Akt and RAS/MAPK 
pathways [14, 62]. Some patients, for whom EGFR-TKI is recommended, have a mutated EGFR 
that is constitutively activated. For these individuals the use of EGFR-TKI is recommended over 
chemotherapy as first line of treatment [22-23]. Although EGFR TKIs have been shown to 
prolong life, most patients acquire resistance with a median progression-free survival of 10 
months [63] and eventually die of metastatic disease. 
Hsp27 is a stress-induced molecular chaperone that regulates many pro-survival cellular 
functions. Many solid tumors, including bladder, prostate, breast and colorectal cancers, express 
high Hsp27 levels that correlate with poor prognosis. Hsp27 maintains protein homeostasis by 
stabilizing protein conformation or facilitating proteasomal degradation [31-40], inhibits 
apoptosis by interacting with pro-apoptotic molecules like cytochrome c [64] or pro-caspase 3 
[65], and enhances oncogenic signaling pathways such as STAT3, IGF-1, androgen receptor 
(AR), and eIF4E [38, 53, 66]. Consistent with these multiple cytoprotective functions, 
overexpression of Hsp27 renders cancer cells resistant to chemo- and hormonal- therapy [36, 
38].  
Since Hsp27 functions as a regulatory “hub” in multiple regulatory pathways, its inhibition will 
simultaneously suppress many pathways implicated in cancer progression and resistance to hormone- 
and chemo-therapies. Hsp27 acts through an ATP-independent mechanism and is therefore not 
amenable to inhibition by 17-AAG derived small molecules.  Strategies to inhibit Hsp27 at the 
mRNA level are an alternative approach to inhibiting “non-druggable” targets; indeed, short 
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interfering RNA (siRNA) or antisense oligonucleotides targeting Hsp27 suppresses proliferation 
and EMT in prostate [33, 38, 67] and breast cancer cells [68]. Hsp27 silencing also decreases 
clonogenic survival and induces cell senescence in HCT116 human colon cancer [69].  Hsp27 
silencing chemo-sensitizes SK-BR-3 HR breast cancer cells to Herceptin [70], A549 lung cancer 
cells to 17-AAG [71], MUC-3 bladder cancer cells and PC-3 prostate cancer cells to paclitaxel 
[43, 67].  Targeting Hsp27 is changeling because of the high dynamic structure of the protein 
that adapt its size to the cellular context, facilitating cancer survival. Using a combined 
biochemical screening, we identified the first small molecule, VPC-27, able to inhibit Hsp27. 
This drug affects Hsp27 phosphorylation and thus inhibits Hsp27 binding to unfolded proteins, a 
fundamental Hsp27 function to protect the cells from the death. However, we do not have 
enough data, at the moment, to understand the exact molecular mechanism of Hsp27 inhibition 
by this drug. The inhibition of the phosphorylation reduces the production of Hsp27 dimers, 
described as the most active forms [72]. 
Moreover, VPC-27 also modified the equilibrium of the Hsp27 oligomers, from the smallest 
(more active) to the biggest (less active). Whether or not this shift is the cause or the effect of the 
inhibition of the phosphorylation is under investigations. 
In this study we show that Hsp27 and phospho-Hsp27 are commonly expressed in a TMA of 440 
squamous cell carcinomas, adenocarcinomas and large cell carcinomas of the lung. We also 
show that treatment stress with erlotinib or chemotherapy increases Hsp27 expression via the 
transcription factor HSF-1 and that high levels of Hsp27 induces resistance to erlotinib. These 
findings implicate a role for Hsp27 in cell survival of NSCLC under EGFR inhibition, and 
supports testing co-targeting Hsp27 with erlotinib or other chemotherapeutics for the treatment 
of NSCLC. Inhibition of treatment-induced Hsp27 using OGX-427 or VPC-27 synergistically 
enhanced inhibitory effects of erlotinib on cell proliferation and cell viability in NSCLC cell 
lines in vitro. Similarly, combination therapy with erlotinib plus OGX-427 or VPC-27 
significantly inhibited A549 and HCC827 tumor growth in vivo compared to monotherapy. 
Consistent with these results, Hsp27 is up-regulated by HSF-1 in c-MET addicted gastric cell 
lines when c-MET is inhibited, and functions to limit the activity of c-MET-targeted therapies 
[73]. In this gastric cell line, the activation of K-RAS by transfection of G12V K-RAS 
downstream of c-MET reverses the effect of c-MET inhibitors on Hsp27 up-regulation [73].  We 
observed an increase of Hsp27 even in A549 lung cancer cells that have a constitutively 
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activated MAP kinase pathway due to a K-RAS activating mutation (G12S), demonstrating that 
in A549 lung cancer cells, Hsp27 up-regulation via HSF-1 is a response to EGFR inhibition even 
when the MAP kinase pathway is constitutively active.   
These results provide a framework for building new drug combinations based on mechanism-
based interventions to overcome drug resistance, and pre-clinical proof-of-principle supporting 
clinical trials of OGX-427 combination regimens for lung and other cancers. OGX-427 has 
completed single agent and docetaxel-combination dose escalation Phase I trials in prostate, 
bladder, breast, and lung cancer [46-48]. OGX-427 is well tolerated, with the majority of the 
adverse events reported being Grade 1 or Grade 2, although a symptom complex of rigors, 
pruritus, and erythema during or shortly after infusion of drug has required steroid prophylaxis 
and/or treatment in some patients at higher doses. Preliminary data from a randomized phase II 
trial of OGX-427 plus prednisone in castration resistant prostate cancer reported a PSA decline ≥ 
30% in 55% of patients and an acceptable safety profile [47]. Several randomized Phase II trials 
of OGX-427 in combination with chemotherapy are actively accruing, including untreated Stage 
IV NSCLC comparing carboplatin plus pemetrexed with or without OGX-427 (SPRUCE, 
clinicaltrials.gov NCT01829113).   
 
CONCLUSIONS 
To summarize, we have identified the first Hsp27 small molecule inhibitor, VPC-27, which 
showed to efficiently inhibit Hsp27 phosphorylation and leads the way for an entirely new 
strategy to inhibit Hsp27. Further research is ongoing to better understand the exact mechanism 
of action of VPC-27, a very promising drug. The functional and transcriptional inhibition of 
Hsp27 induces a significant inhibition of NSCLC tumor proliferation in vitro and in vivo. 
Overall, small molecule inhibitors of Hsp27 could represent a valid therapeutic strategy to 
improve survival of patients affected by metastatic NSCLC. 
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